CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark

Journal of the National Cancer Institute

Volumn 103, Issue 6, 2011, Pages 489-500

  Lash, Timothy L ^a,b,c   Cronin Fenton, Deirdre ^a   Ahern, Thomas P ^b   Rosenberg, Carol L ^c   Lunetta, Kathryn L ^b   Silliman, Rebecca A ^c   Garne, Jens Peter ^d,e   Sørensen, Henrik Toft ^a,b,e   Hellberg, Ylva ^a   Christensen, Mariann ^a   Pedersen, Lars ^a   Hamilton Dutoit, Stephen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e Danish Breast Cancer Cooperative Group (DBCG)   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALAPROCLATE; ANTINEOPLASTIC AGENT; CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 INHIBITOR; ESCITALOPRAM; ESTROGEN RECEPTOR; ETOPERIDONE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; UNCLASSIFIED DRUG; ZIMELDINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DRUG INHIBITION; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; MONTE CARLO METHOD; NULL ALLELE; PARTIAL MASTECTOMY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYTOCHROME P-450 CYP2D6; DENMARK; ENZYME INHIBITORS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MEDICATION ADHERENCE; MIDDLE AGED; MONTE CARLO METHOD; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79952838781     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr010     Document Type: Article

References (72)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
2. Wolf DM, Gottardis MM, Jordan VC. Tamoxifen-resistant growth. In: Jordan VC, ed. Long-Term Tamoxifen Treatment for Breast Cancer.Madison, WI: University of Wisconsin Press; 1994:181-198.
3. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643-658. (Pubitemid 40065543)
4. Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices-point. Cancer Epidemiol Biomarkers Prev. 2007;16(11): 2207-2209.
5. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett. 2007;256(1):1-24. (Pubitemid 47333324)
6. Milano A, Dal LL, Sotiriou C, Piccart M, Cardoso F. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer. 2006;42(16):2692-2705. (Pubitemid 44584668)
7. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 95(23):1758-1764. (Pubitemid 38008898)
8. Coller JK, Krebsfaenger N, Klein K, et al. The infuence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioes-trogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol. 2002; 54(2):157-167. (Pubitemid 35024939)
9. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977;75(2):305-316. (Pubitemid 8219148)
10. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identifcation of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 1988;48(8):2304-2308.
11. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cyto-chrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075. (Pubitemid 39108928)
12. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471-478. (Pubitemid 40568978)
13. Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol. 2008;19(1):56-61.
14. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
15. Desta Z, Flockhart DA. Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol. 2007;25(33):5147-5149. (Pubitemid 350232242)
16. Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 2007;72(13):829-842. (Pubitemid 47410069)
17. American Cancer Society. Tamoxifen: some women don't get full beneft. American Cancer Society 2006. www.cancer.org/docroot/NWS/content/ NWS 1 1x Tamoxifen Some Women Dont Get Full Beneft.asp. Last accessed November, 2008.
18. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for refection? Lancet Oncol. 2009;10(8): 825-833.
19. Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the beneft of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005;7(3):R284-R290.
20. Okishiro M, Taguchi T, Jin KS, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952-961.
21. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxi-fen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005;91(3):249-258. (Pubitemid 40903087)
22. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9(1):R7.
23. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121. (Pubitemid 47555336)
24. Newman WG, Hadfeld KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res. 2008;14(18):5913-5918.
25. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193. (Pubitemid 350232249)
26. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
27. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant ta-moxifen therapy. Cancer Sci. 2008;99(5):995-999. (Pubitemid 351997603)
28. Gor PP, Su HI, Gray RJ, et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010;12(3):R26.
29. Ramon y Cajal T, Altes A, Pare L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010;119(1):33-38.
30. Thompson AM, Johnson A, Quinlan P, et al. Comprehensive. . CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125(1):279-287.
31. Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene variants: association with breast cancer specifc survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 2010;12(4):R64.
32. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
33. Kiyotani K, Mushiroda T, Imamura CK, et al. Signifcant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8):1287-1293.
34. Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A. Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol. 2004;44(8):861-865. (Pubitemid 38971567)
35. Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer. 2008;99(4):616-621.
36. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2562-2564.
37. Lash TL, Cronin-Fenton D, Ahern TP, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 2010;49(3):305-312.
38. Aubert RE, Stanek EJ, Yao J, et al. Risk. . of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol. 2009;27(supplement):18S.
39. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693.
40. Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28(14): 2423-2429.
41. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat. 2008;112(1):123-132.
42. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group-DBCG: history, organization, and status of scientifc achievements at 30-year anniversary. Acta Oncol. 2008;47(4):497-505. (Pubitemid 351878432)
43. Union for International Cancer Control. TNM Classifcation of Malignant Tumours. 5th ed. Geneva, Switzerland: Springer; 1997.
44. Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506-524. (Pubitemid 351878431)
45. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142(12):1255-1264. (Pubitemid 26006424)
46. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
47. Talman ML, Rasmussen BB, Andersen J, Christensen IJ. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol. 2008;47(4): 789-794.
48. Lash TL, Fox MP, Thwin SS, et al. Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol. 2007;165(12):1454-1461. (Pubitemid 47234311)
49. Thwin SS, Clough-Gorr KM, McCarty MC, et al. Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol. 2007;7(June 18):23.
50. Silliman RA, Guadagnoli E, Rakowski W, et al. Adjuvant. tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol. 2002;20(11):2680-2688. (Pubitemid 34575641)
51. Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol. 1988;27(6A).
52. Weir B. Genetic Data Analysis II: Methods for Discrete Population Genetic Data. Sunderland, MA: Sinauer Associates; 1996.
53. Lash TL, Fox MP, Fink AK. Applying Quantitative Bias Analysis to Epidemiologic Data. New York, NY: Springer; 2009.
54. Schroth W, Hamann U, Fasching PA, et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratifcation. Clin Cancer Res. 2010;16(17):4468-4477.
55. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant ta-moxifen therapy: results of a meta-analysis. Breast Cancer Res Treat. 2010;122(3):609-617.
56. Ahern TP, Larsson H, Garne JP, Cronin-Fenton DP, Sorensen HT, Lash TL. Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol. 2008;23(2):109-114.
57. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284-295. (Pubitemid 27058401)
58. Myrand S, Sekiguchi K, Man M, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and frst- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347-361.
59. Erichsen R, Lash TL, Hamilton-Dutoit S, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010 (August 9);2:51-56.
60. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100(3):218-221. (Pubitemid 351480544)
61. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription poly-merase chain reaction by central laboratory. J Clin Oncol. 2008;26(15): 2473-2481.
62. Jensena AR, Ewertz M, Cold S, Storm HH, Overgaard J. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur J Cancer. 2003; 39(12):1783-1793. (Pubitemid 36897617)
63. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549-555. (Pubitemid 351264347)
64. Geiger AM, Thwin SS, Lash TL, et al. Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer. 2007;109(5):966-974. (Pubitemid 46333538)
65. Rae JM, Sikora MJ, Henry NL, et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009;9(4):258-264.
66. Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol. 2002;31(1).
67. Lash TL, Rosenberg CL. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol. 2010;28(8):1273-1275.
68. Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL. Re: active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2004;96(11):883-885. (Pubitemid 38807611)
69. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4(2):45-61. (Pubitemid 44698579)
70. Kavvoura FK, McQueen MB, Khoury MJ, Tanzi RE, Bertram L, Ioannidis JP. Evaluation of the potential excess of statistically signifcant fndings in published genetic association studies: application to Alzheimer's disease. Am J Epidemiol. 2008;168(8):855-865.
71. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361(9360):865-872. (Pubitemid 36331853)
72. Peters BJ, Rodin AS, de BA, Maitland-van der Zee AH. Methodological and statistical issues in pharmacogenomics. J Pharm Pharmacol. 2010;62(2):161-166.